www.fdanews.com/articles/193506-reblozyl-earns-fdas-first-approval-for-rare-blood-disorder
![ApprovedGreen.gif](https://www.fdanews.com/ext/resources/test/Drug-Images3/ApprovedGreen.gif?t=1576044289&width=430)
Reblozyl Earns FDA’s First Approval for Rare Blood Disorder
November 19, 2019
Celgene and Acceleron’s Reblozyl (luspatercept-aamt) earned FDA approval for treatment of anemia in adults with beta thalassemia who require regular red blood cell transfusions.
The agency granted the approval based on the results of a clinical trial of 336 patients with beta thalassemia who required transfusions. Twenty-one percent of the patients who received Reblozyl achieved at least a 33 percent reduction in transfusions compared to 4.5 percent of the patients who received a placebo.
Reblozyl is the first FDA-approved treatment for Cooley’s anemia. It was previously granted both fast track and orphan drug designations.